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Abstract: New models of drug discovery have been developed to overcome the lack of modern 
and effective drugs for neglected diseases such as human African trypanosomiasis (HAT; sleeping 
sickness), leishmaniasis, and Chagas disease, which have no financial viability for the pharmaceuti-
cal industry. With the purpose of combining the skills and research capacity in academia, phar-
maceutical industry, and contract researchers, public–private partnerships or product development 
partnerships aim to create focused research consortia that address all aspects of drug discovery and 
development. These consortia not only emulate the projects within pharmaceutical and biotechnol-
ogy industries, eg, identification and screening of libraries, medicinal chemistry, pharmacology 
and pharmacodynamics, formulation development, and manufacturing, but also use and strengthen 
existing capacity in disease-endemic countries, particularly for the conduct of clinical trials. The 
Drugs for Neglected Diseases initiative (DNDi) has adopted a model closely related to that of a 
virtual biotechnology company for the identification and optimization of drug leads. The applica-
tion of this model to the development of drug candidates for the kinetoplastid infections of HAT, 
Chagas disease, and leishmaniasis has already led to the identification of new candidates issued from 
DNDi’s own discovery pipeline. This demonstrates that the model DNDi has been implementing 
is working but its DNDi, neglected diseases sustainability remains to be proven.
Keywords: R&D, screening, lead optimization, human African trypanosomiasis, leishmaniasis, 
Chagas disease, product development partnerships
Introduction
Neglected tropical diseases (NTDs), as defined by the World Health Organization (WHO), 
refer to infectious diseases that occur within the tropical belt and include – but are not 
limited to – malaria, leishmaniasis, schistosomiasis, onchocerciasis, lymphatic filariasis, 
Chagas disease, African trypanosomiasis, and dengue.1–4 These diseases are responsible 
for substantial morbidity and mortality in the developing world and have a clear eco-
nomic burden on the affected countries.5,6 During 1975–2004, only 21 (1.3%) out of 1556 
approved drugs were specifically developed to address NTDs, even though NTDs account 
for 11.4% of the global disease burden.7 The lack of a profitable market and effective 
mechanisms related to public health policy, financing, and drug discovery and develop-
ment expertise and capacity has largely contributed to this low achievement.8 Yet, the 
landscape has dramatically changed in the past 5 years.9 Indeed, the emergence of product 
development partnerships (PDPs) is filling the existing research and development (R&D) 
gap and creating bridges between the various private and public stakeholders.10,11
The immediate needs of the most neglected patients affected by NTDs are, how-
ever, still largely unmet. A recent study by G-FINDER12 has revealed that less than Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
176
Chatelain and Ioset
5% of worldwide R&D funding for NTDs has been directed 
towards the most neglected diseases, such as human African 
trypanosomiasis (HAT), visceral leishmaniasis, and Chagas 
disease, although more than 500 million people are at risk.13 
By building partnerships in both the public and the private 
sector, based on existing capacity, expertise, and resources, 
DNDi is working to foster R&D for NTDs that continue to 
affect millions of people worldwide.
DNDi: the organization  
and its objectives
DNDi is a not-for-profit drug R&D organization based in 
Geneva, Switzerland, founded in 2003 by seven institutions: 
the Indian Council for Medical Research (ICMR), the Kenya 
Medical Research Institute (KEMRI), the Malaysian Ministry 
of Health, the Oswaldo Cruz Foundation in Brazil, Médecins 
Sans Frontieres (MSF), the Institut Pasteur in France, and 
the Special Programme for Research and Training in Tropical 
Diseases (TDR). The aim was to create an organization that 
would respond to the dire need of safe, affordable,   easy-  to-use 
and efficacious treatments for neglected patients.14
DNDi’s main short-term objectives are to deliver 6–8 new 
treatments for HAT, Chagas disease, visceral leishmaniasis, 
and malaria by 2014 and, at the same time, to address the 
immediate needs of affected patients with a sense of urgency. 
DNDi also aims to establish a robust R&D portfolio that 
covers the entire drug discovery process, from early-stage 
discovery to clinical development and distribution, to respond 
to patient needs for better, effective, safe, adequate, and 
  accessible new treatments.
Moreover, DNDi aims to use and strengthen existing 
capacities in disease-endemic countries and to raise aware-
ness about the need to develop new drugs for NTDs and 
advocate for increased public responsibility.
DNDi: R&D strategy
To achieve its ambitious goals, DNDi has built a solid and 
well balanced portfolio that spans the entire drug develop-
ment pipeline for kinetoplastid diseases (Figure 1). With a 
strategic approach to identify and bridge the gaps across 
the drug development pipeline, DNDi has undertaken 
both middle/short-term and long-term projects. Short- and 
medium-term projects aim to deliver new treatments by 2014. 
Long-term projects aim to establish a solid pipeline for new 
drugs after 2014.
DNDi builds its portfolio by identifying projects that 
fall into the following five categories, based on the nature 
of the compound/treatment under consideration and accord-
ing to its stage of development or expected time to reach 
patients:
•	 New drug candidates identified through screening and 
lead optimization efforts
•	 New molecules associated with an advanced   development 
profile – the so-called “low-hanging fruits” or “  oldies” 
(could start at lead optimization or pre-clinical 
development)
•	 New indications for existing medicines in the field of the 
most neglected diseases (ie, therapeutic switching, drug 
repositioning)
Discovery
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Exploratory
Exploratory
HAT LO 
Consortium
• Scynexis
• Pace Univ
VL LO
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• Advinus
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• Sources for hit and lead compounds:
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LSHTM, Swiss Tropical Institute, 
University of Antwerp
Figure 1 DNDi portfolio as of January 2010.
Abbreviations: R: research, LS: lead selection, LO: lead optimisation, CDRI: Central Drug Research Institute (India), CDCO: Centre for Drug Candidate Optimisation 
(Australia), FUOP: Federal University of Ouro Preto (Brazil), GNF: Genomics Institute of the Novartis Research Foundation, NITD: Novartis Institute for Tropical Diseases, 
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•	 New formulations and combinations of existing drugs 
  better adapted to field conditions (ie, pediatric,   long-acting, 
new route of administration, fixed-dose combinations, 
copackaging or coadministration)
•	 Existing drugs for target diseases (ie, geographical exten-
sion of registration, completion of regulatory dossiers of 
existing drug candidates)
DNDi: Discovery and the “S” rule
DNDi has adopted a pragmatic strategy towards drug 
  discovery that has evolved from a hunter-gatherer approach – 
identifying projects mostly based on networking interactions –   
to structured partnerships with pharmaceutical and biotech-
nology companies. The partnerships include Sourcing and 
Screening of compounds followed by the Selection of Series 
to optimize.
Sourcing
Because of limitations in screening throughput and a sense 
of urgency to develop modern medicines for these neglected 
diseases, DNDi has adopted a focused approach to com-
pound sourcing and drug discovery rather than seeking 
to address chemical diversity through random compound 
library screening.
Examples of this focused approach for different stages 
of drug discovery are listed below.
•	 Chemical diversity: access to diversity sets representative 
of libraries from various institutions and   pharmaceutical 
companies; natural products, synthetic compounds, 
  random screening.
•	 Focused drug classes:
○	 Chemical series: accessed mostly through partnership 
with pharmaceutical and biotechnology companies 
with the goal of not only accessing compounds of 
interest but also libraries of analogs, as well as related 
pharmaceutical knowledge and expertise associated 
with those series (eg, oxaboroles at Anacor, pyridones 
at GSK, and macrolides are examples of chemical 
classes under development at DNDi); biologically 
annotated series accelerate over clusters characterized 
only in terms of potency from a library screen.
○	 Classes of inhibitors: inhibitors of specific   biochemical 
pathways are evaluated for their activity against effi-
cacy models with the idea to access library of analogs 
as well as related pharmaceutical   knowledge and 
expertise associated with those series (eg, cysteine 
protease inhibitors at Merck, partnership with 
  University of Dundee’s Drug Discovery Unit).
•	 Data mining/low-hanging-fruit approach: the aim is to 
identify compounds reasonably well characterized from 
a development standpoint, enabling a gain of time and 
resources in terms of potential development provided 
that the profile of such molecules is in line with our R&D 
criteria. Fexinidazole, a nitroimidazole compound cur-
rently in phase I clinical development for HAT at DNDi 
is a good illustration of this approach.15
•	 The DNDi discovery team has also developed strong 
relationships with other PDPs such as the Medicines 
for Malaria Venture (MMV), the Global Alliance for 
TB (TB Alliance), as well as with additional R&D 
industrial institutes/centers active in the field, such as 
the   Novartis Institute for Tropical Diseases. The objec-
tives of these alliances and/or with other PDPs gravi-
tate around exchange of information and experience, 
identification of potential synergies, and avoidance of 
duplication.
Needless to say, the choice of the partner and their 
commitment to neglected diseases is of crucial importance 
to move forward quickly in the process. Indeed, access to 
compounds, but more importantly the knowledge that the 
partner has for a compound class, can have a dramatic impact 
on the need for resources, the pace of the discovery process, 
and nomination of a candidate.
Screening
In contrast to malaria research in which drug targets have 
been identified, validated targets are still very sparse or 
missing for kinetoplastid diseases. For that reason and 
since discrepancy between target and whole-cell screens 
have been widely observed in the frame of several anti-
infective   screening campaigns, DNDi took advantage of 
phenotypic screens to identify active compounds against 
parasites. Indeed, there are no regulatory requirements to 
identify the target of an active compound or its mode of 
action, even if the latter could be helpful during the next 
steps of development.
Historically, the lack of high throughput capacity of 
phenotypic screening assays for kinetoplastid diseases 
has prevented the access to a critical mass of quality hits 
needed for further development considering the high 
attrition rate occurring in discovery programs.16 This is 
especially true for intracellular obligate protozoa such as 
Leishmania   donovani and Trypanosoma cruzi (the causal 
agents of visceral leishmaniasis and Chagas disease, 
respectively). To address this, DNDi has invested consid-
erable effort to develop high-throughput screening (HTS) Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
178
Chatelain and Ioset
assays for all three diseases of interest; in particular, an 
HTS image screening assay, developed in partnership 
with the Institut Pasteur Korea (IPK) and available for the 
relevant intracellular stage of L. donovani, is a key mile-
stone in the field and is expected to change dramatically 
the hit generation dynamics for visceral   leishmaniasis. 
Just recently, the first ever HTS campaign against the 
intracellular form of L. donovani has been completed at 
IPK on a library of 200,000 compounds, a number that is 
most probably larger than the total amount of compounds 
ever tested against Leishmania so far.
Besides HTS assays, DNDi, through its network of 
partners with well established and recognized centers in 
  parasitology, such as the Swiss Tropical Institute and the 
University of Antwerp among others, is able to evaluate and 
confirm activities of compounds issued from HTS campaigns 
with state of the art, low throughput assays both in vitro and 
in vivo.
The phenotypic screen of smaller specific subsets of 
compounds belonging to a certain chemical class or target 
inhibitor could lead to the identification and chemical valida-
tion of targets of interest, making target-based screens more 
attractive in the field of kinetoplastid drug discovery. One 
such target, the parasite phosphodiesterase that is essential 
for Trypanosome brucei and L. donovani, is currently being 
investigated in a collaborative project involving, among oth-
ers, Nycomed, DNDi, and TI Pharma.
Series to optimize
DNDi strives to maintain a full pipeline, which includes 
development of innovative new drugs through long-term 
lead optimization programs. Drug candidate series of inter-
est identified from various screening projects are selected to 
enter the lead optimization process.
For that purpose and because of resources and costs, 
DNDi has created a unique model for lead optimization. 
In short, DNDi has adopted the approach of contracting 
lead optimization teams that are independent from specific 
targets or scaffolds. In doing so, DNDi can feed each team 
with hits and leads that are identified from a range of dif-
ferent sources. Scaffolds that prove not to be amenable to 
optimization can also be discontinued without disrupting 
the research integrity of the dedicated lead optimization 
team.
To maintain the capacity for optimizing one lead series at 
all times, each team consists of five or six chemists, two or 
three pharmacologists, and a dedicated screening facility to 
assess potency and efficacy with guaranteed infrastructure to 
support medicinal chemistry, in vitro and in vivo   distribution- 
metabolism-pharmacokinetic (DMPK),   toxicology, and 
efficacy studies.
To produce new drug candidates as efficiently as pos-
sible, all players should be focused on the lead   optimization 
program and not distracted by other research efforts. 
To that end:
•	 Once a lead is introduced into a lead optimization pro-
gram, it enters a critical path17 that promises develop-
ment to patient access unless the compound series fails 
because structural liabilities prevent optimization as a drug 
candidate
•	 Sufficient resources are allocated to guarantee the rapid 
turnaround of data necessary to support the medicinal 
chemistry effort
•	 A research group associated with the program is encour-
aged to pursue more discovery research associated with 
the disease so that the lead optimization programs are 
constantly fed with promising leads. Therefore, a sepa-
rate group of staff conducts the supporting assays for 
lead optimization and commits 100% of its time to the 
medicinal chemistry effort.
To date, DNDi has brought together four lead optimiza-
tion teams, two for HAT, one for visceral leishmaniasis, and 
one for Chagas. DNDi works with companies and partners 
that are committed to research for NTDs. Researchers are 
funded as fee-for-service contractors and make no claim to 
any intellectual property generated during the lead optimi-
zation programs. Therefore, DNDi is free to manage the 
intellectual property in a way that is most appropriate to 
guarantee access for those affected by NTDs.
Support/selection of the candidate
To prioritize and select compounds and series, and advance 
them through the drug development process, DNDi has 
developed a set of tools and consulting committees to support 
its decision-making process.18 These include target product 
profiles (TPPs) for each disease for both new chemical enti-
ties (NCEs) and combination treatments, drug discovery 
manuals, decision matrices, Web-based data management, 
and a network of consultants to act as critics and mentors.
Precise and concrete criteria have also been compiled 
at the preclinical stage to define profiles of hits, leads, 
optimized leads, and drug preclinical candidates for HAT, 
visceral leishmaniasis, and Chagas disease. These criteria – 
  typically including in vitro and in vivo efficacy data,   chemical 
features such as compound tractability and druggability, 
absorption-distribution-metabolism-excretion (ADME), Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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and toxicity parameters – are described in the DNDi Drug 
Discovery and Development Manual.
Target product profiles
TPPs are an organized list that prioritizes key features of the 
drug and guides investigators to work in an orchestrated way.19 
Therefore, TPPs are the basis of all drug discovery management 
tools designed to support lead optimization programs.
DNDi is a needs-driven organization (ie, the needs of 
patients suffering from NTDs are the driving force for 
all drug discovery and development programs). DNDi, 
through consultation with expert committees that include 
stakeholders such as physicians, local disease control 
programs, regulators, and patient representatives, as well 
as local and global public health organizations, is able to 
draft TPPs. Therefore, TPPs define effective therapies for 
patients in every-day field conditions (see Table 1 for an 
example of TPP).
Discovery manuals
To direct progression of compound during the drug discov-
ery process, drug discovery manuals for each disease are 
prepared to define key decision points and provide objective 
measures for making decisions, taking into account potency, 
physicochemical properties and in vitro and in vivo DMPK/
toxicity. Examples of progression criteria as part of the 
  discovery process for neglected diseases have been described 
by Nwaka et al.20 The major decision points are listed below 
and shown in Figure 2.
•	 Hit selection: The decision to proceed to in vivo studies 
and hit expansion based on the identification of a single 
compound from library screening or literature search.
•	 Lead selection: The decision to proceed to chemical 
optimization based on review of a series of chemical 
analogues of the hit compound.
•	 Optimized lead selection: The decision to proceed to regu-
latory preclinical toxicology (GLP [Good Laboratory Prac-
tice] Toxicology) and GMP (Good Manufacturing Practice) 
pharmaceutical development of one compound or a small 
number of compounds from the same chemical class.
•	 Drug candidate selection: The decision to proceed to 
clinical evaluation of one compound or a small number 
of compounds from the same chemical class.
In addition, key activities and partners are listed for each 
stage of drug discovery to ensure that sufficient resources 
are allocated to the program and that research progresses in 
the shortest timeframe as activities are conducted in   parallel 
wherever possible. At each decision point, the   information 
may result in a go/no go decision. In some instances, it 
may highlight additional research required before fully 
  committing to the next stage of drug discovery.
The key activities for each decision point and the expected out-
comes for these activities are defined to guarantee that continued 
development will address the expectations defined by the TPP.
Decision matrices
The decision matrix is an operational tool designed to support 
the drug discovery manual. In addition to the key assays 
Table 1 Target product profile  for developing combinations from existing VL treatments and NCEs
For VL combinations of existing VL treatments For VL NCEs
Target label vL vLa
Species All species All species
Distribution All areas All areas
Target population Immunocompetent and immunosuppressed,  
adults and children
Immunocompetent and immunosuppressed,  
adults and children
Clinical efficacy .95% (phase 3) .95% 
Resistance Active against resistant strains Active against resistant strains
Safety and tolerability No Aes requiring patient monitoring No Aes requiring monitoring
Contraindications None/few as defined by current drugs None
Interactions None – compatible for combination therapy
Formulation A mix of iv, im ± oral Oral/im depot
Treatment regimen #10 day treatment 1/day for 10 days po/3 shots im over 10 days
Feasibility Most of treatment given as outpatient  
(eg, oral treatment)
Outpatient management with minimal follow-up
Stability As defined by current drugs 3 years in zone Iv
Cost #US$75/course ,US$10/course
Notes: aNCe should ideally also target PKDL. TPPs are revised on a regular basis.
Abbreviations: Ae, adverse event; iv, intravenous; im, intramuscular; NCe, new chemical entity; PKDL, post-kala-azar dermal leishmaniasis; po, orally; vL, visceral 
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specified for the decision points, simpler   surrogate assays 
are listed to enable more rapid screening of   molecules that 
are   synthesized as part of medicinal chemistry   programs. 
A   simple spreadsheet, in which values for each new   compound 
are entered, allows for ready comparison with ideal and 
acceptable values. By color coding the cells on the basis of the 
value entered, it is possible to rapidly assess   progress during 
the synthesis of a particular chemical series.
In addition, it is recommended that representative com-
pounds from the main classes with defined biological activity 
should be regularly tested to assess the true predictive value 
of the surrogate assays.
Data management
Regular and spontaneous communication between all mem-
bers of a research team is essential for efficient progression of 
a lead optimization program. In most cases, not all members 
are located at the same site.
To provide all participants ready access to generated 
data, DNDi uses a proprietary Web-based data management 
system. All researchers enter data in templates that have been 
formatted to suit the data they generate, either chemical or 
biological. The data are structure and substructure searchable, 
and every researcher can review all data within the context of 
their specific expertise. A Web-based portal can store files in 
various formats and is used for circulation of reports and for 
storing complex supporting data and background information 
such as papers and patents.
Expert committees
DNDi works with consultants who are expert in different dis-
ciplines to provide ongoing critical review of the programs. 
The programs are also regularly reviewed by the Scientific 
Advisory Committee of DNDi which is formed by prominent 
scientists with expertise in various scientific disciplines.
Achievements and next challenges
The PDP for NTD drug development relies on strong 
  partnerships between industry and academia, and on   sharing 
of knowledge that is often held as proprietary by   different 
partners. In addition to the application of best research 
practices (eg, TPPs, drug discovery manuals, critical path), 
  building of trust and open communication are crucial to 
s  uccess. Although the concept of the PDP is still in its infancy, 
many productive alliances have been built. For example, 
DNDi-coordinated Fixed-Dose Artesunate-Containing 
Therapy (FACT) Project Consortium was developed and made 
available two new improved treatments for malaria. In 2007, 
DNDi in collaboration with sanofi-aventis, registered its first 
product, the antimalarial artesunate-amodiaquine fixed-dose 
combination (ASAQ), by applying its innovative R&D model 
for the treatment of   noncomplicated   Plasmodium falciparum 
1–2 chemists
basic DMPK
efficacy
6 chemists
2 biologists (DMPK/tox)
efficacy
Defined by TPP
Screening
Hit expansion
Mode of action
Reiterative cycles of
medicinalchemistry
Parallel assessment
of DMPK tox and
potency
Pharmaceutical
chemistry
GLP Toxicology
Drug
candidate
Parasitology
• Biology/targets
• Pathology/targets
• Chemistry/targets
Drug discovery (product development)
Commit to clinical research (critical path)
• ADME
• Pharmacokinetics
• Toxicology
• Pharmacodynamics
6–9 months 24–30 months 12–15 months
CROs, partners
Hits 3–4 scaffolds
DDM DDM DDM
1 scaffold
Lead to candidate Lead optimization
Figure 2 DNDi’s drug discovery process with decision-making tools and key decision points.
Abbreviations: ADME, absorbtion-distribution-metabolison-excretion; DDM, drug discovery manual; TPP, target product profile; DMPK, distribution-metabolison-pharmace-
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malaria. In 2008, DNDi in partnership with a   public   institution 
(  Farmanguinhos, Brazil) launched its second product for 
malaria, artesunate-mefloquine fixed-dose combination 
(ASMQ) in Brazil using a similar model. In 2009, following 
the results of a Phase 3 clinical trial testing the efficacy 
of a   combination treatment of nifurtimox and   eflornithine 
(NECT) against stage 2 HAT, nifurtimox was added to WHO 
Essential   Medicine List for the treatment of HAT. NECT is 
  recommended by WHO for the treatment of HAT.
More importantly, candidates issued from DNDi dis-
covery pipeline are now starting to move forward towards 
preclinical and clinical development, indicating the   emerging 
success of the strategy of the PDP model for NTD drug 
discovery and development.
There is, however, a need to carry on strengthening our 
existing preclinical pipeline to cope with the attrition rate 
inherent to any R&D activity. The identification of novel lead 
series and clinical candidates supported by strong backup 
programs is indeed key to ensure a timely delivery of new 
treatments for patients suffering from neglected diseases.
Finally, awareness towards those affected by NTDs still 
needs to be increased. We indeed strongly believe it is only 
by raising awareness that we can ensure that truly modern 
treatments (safe, efficacious, easy to administer) and funding 
will be made available.
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